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Dear Sir,
We read with great interest the "Recommendations 
for the use of albumin and immunoglobulins" 
by Liumbruno and colleagues on behalf of the 
Italian Society of Transfusion Medicine and 
Immunohematology (SIMTI), recently published 
in Blood Transfusion1. We noted that acquired von 
Willebrand syndrome (AVWS) is listed in Table III 
among the inappropriate indications for the use of 
intravenous immunoglobulins (IVIG). Although the 
reported level of evidence is particularly low (2C), 
we do not agree with such a strong statement. In 
fact, according to our direct experience with AVWS 
patients for the last 20 years, we believe that IVIG 
should actually be considered at least as an useful 
additional therapeutic approach for the management 
of bleeding of these patients2-5.
AVWS is a rare bleeding disorder similar to inherited 
von Willebrand's disease in terms of laboratory 
fi ndings and clinical severity. It is characterised by 
a prolonged bleeding time and variably low plasma 
levels of von Willebrand factor (VWF) and factor VIII 
(FVIII). The syndrome usually occurs in individuals 
with no personal or family history of bleeding. 
Since the original description of AVWS in 1968, in 
a patient with systemic lupus erythematosus3,5, more 
than 300 cases of AVWS have been reported. Several 
review articles have been published, and data from an 
International Registry on AVWS are also available3. 
Six categories of underlying disorders have been 
reported to occur frequently in patients with AVWS: 
lymphoproliferative and myeloproliferative disorders; 
solid tumours; immunological and cardiovascular 
disorders; and miscellaneous conditions. Taken 
together, lymphoproliferative and myeloproliferative 
disorders appear to be most frequently associated 
with AVWS in both the literature and the registry, 
accounting for 48-63% of cases3. However, in a 
retrospective study Thiede et al. found a relatively 
high association with cardiovascular disorders 
(46%) in comparison to monoclonal gammopathy 
(31%), which is usually reported as the most frequent 
underlying disorder5. 
Data from large prospective studies are not 
available and the actual prevalence of AVWS in the 
general population is, therefore, unknown. In the 
only prospective study available, the prevalence 
was approximately 10% in 260 patients with 
haematological disorders enrolled by a single 
institution5. According to these observations, 
the number of patients with AVWS is certainly 
underestimated, because most AVWS patients do 
not bleed until they are exposed to major trauma or 
major invasive procedures and surgery5.  Compared 
with acquired haemophilia A, which is always due to 
auto-antibodies against FVIII, a variety of pathogenic 
mechanisms have been proposed to cause structural 
or functional disturbances of VWF3,5. These include 
autoantibodies, either interfering with platelets 
or collagen binding or increasing VWF clearance 
from the plasma5. Sequestration of  high-molecular 
weight multimers was demonstrated in patients 
with haematological disorders due to adsorption 
to myeloma cells or platelets, but also in reactive 
thrombocytosis. Proteolytic cleavage of VWF can 
occur after shear stress-induced unfolding, and AVWS 
due to this mechanism was described in disorders 
with increased shear stress, in particular aortic valve 
stenosis and left ventricular assist devices. Proteolytic 
cleavage has also been described in patients with 
pancreatitis, liver cirrhosis and leukaemia and in 
those taking certain medications. In hypothyroidism, 
AVWS seems to result from decreased synthesis of 
otherwise normal VWF5. 
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The management of AVWS is targeted in two 
main directions: treatment of the underlying medical 
condition (with surgery, chemotherapy, radiotherapy 
and/or immunosuppressants), which can result in 
remission of AVWS, and correction of the acute 
bleeding episode3,5. The treatment options for this 
latter purpose include desmopressin, VWF-containing 
concentrates, plasmapheresis, recombinant factor 
VIIa and IVIG3,5. In particular, the clinical use 
of IVIG in AVWS has been described by several 
authors2,5, and the results from the International 
Registry reported an overall success rate of 33% 
(21 of 63 cases) for this treatment, which was 
more effective in lymphoproliferative disorders (18 
[37%] of 48), solid tumours (2 [100%] of 2) and 
immunological diseases (1 [50%] of 2)3. IVIG seem 
to be especially useful in AVWS cases associated 
with monoclonal gammopathy of undetermined 
significance (MGUS)2,5. In the prospective trial, 
which enrolled 10 patients with AVWS and MGUS, 
IVIG were more effective than desmopressin or VWF/
FVIII concentrates because they induced a prompt 
and sustained increase of FVIII/VWF activities and 
shortened the bleeding time for at least 15 to 20 days 
in all IgG-MGUS cases. By contrast, no response was 
observed in AVWS patients with MGUS of the IgM 
class (IgM-MGUS) 2. The mechanism of action of 
IVIG in this setting is unclear but could involve an 
anti-idiotype effect, blockage of reticulo-endothelial 
Fc-receptors or elimination of circulating immune 
complexes by circulating immunoglobulin2,4.
In conclusion, the published literature document 
that IVIG are an important therapeutic option for 
the management of AVWS cases, especially those 
associated with IgG-type monoclonal gammopathies. 
As a consequence, we suggest that the next revision 
of the recommendations will take in account our 
comments and that AVWS will be included in the 
list of non-recognised conditions in which IVIG have 
been used with some benefi t.
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